» Articles » PMID: 39940737

Metabolic Profiling of Breast Cancer Cell Lines: Unique and Shared Metabolites

Abstract

Breast Cancer (BrCa) exhibits a high phenotypic heterogeneity, leading to the emergence of aggressive clones and the development of drug resistance. Considering the BrCa heterogeneity and that metabolic reprogramming is a cancer hallmark, we selected seven BrCa cell lines with diverse subtypes to provide their comprehensive metabolome characterization: five lines commonly used (SK-Br-3, T-47D, MCF-7, MDA-MB-436, and MDA-MB-231), and two patient-derived xenografts (Hbcx39 and Hbcx9). We characterized their endometabolomes using H-NMR spectroscopy. We found distinct metabolite profiles, with certain metabolites being common but differentially accumulated across the selected BrCa cell lines. High levels of glycine, lactate, glutamate, and formate, metabolites known to promote invasion and metastasis, were detected in all BrCa cells. In our experiment setting were identified unique metabolites to specific cell lines: xanthine and 2-oxoglutarate in SK-Br-3, 2-oxobutyrate in T-47D, cystathionine and glucose-1-phosphate in MCF-7, NAD in MDA-MB-436, isocitrate in MDA-MB-231, and NADP in Hbcx9. The unique and enriched metabolites enabled us to identify the metabolic pathways modulated in a cell-line-specific manner, which may represent potential candidate targets for therapeutic intervention. We believe this study may contribute to the functional characterization of BrCa cells and assist in selecting appropriate cell lines for drug-response studies.

References
1.
Ter Brugge P, Moser S, Bieche I, Kristel P, Ibadioune S, Eeckhoutte A . Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers. Nat Commun. 2023; 14(1):1958. PMC: 10082194. DOI: 10.1038/s41467-023-37537-2. View

2.
Lacroix M, Leclercq G . Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat. 2004; 83(3):249-89. DOI: 10.1023/B:BREA.0000014042.54925.cc. View

3.
Grassilli S, Vezzali F, Cairo S, Brugnoli F, Volinia S, De Mattei M . Targeting the Vav1/miR‑29b axis as a potential approach for treating selected molecular subtypes of triple‑negative breast cancer. Oncol Rep. 2021; 45(5). DOI: 10.3892/or.2021.8034. View

4.
Jena M, Janjanam J . Role of extracellular matrix in breast cancer development: a brief update. F1000Res. 2018; 7:274. PMC: 6020719. DOI: 10.12688/f1000research.14133.2. View

5.
Lehmann B, Jovanovic B, Chen X, Estrada M, Johnson K, Shyr Y . Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6):e0157368. PMC: 4911051. DOI: 10.1371/journal.pone.0157368. View